All In Biotech

Drug Trial Radar · NCT04636515

A Phase Ⅱ Study of F520 in Patients With Urothelial Carcinoma

A Phase 2, Open-label, Single-arm,Multicenter Study of F520 in Patients With Urothelial Carcinoma

Last checked: Nov 19, 2026Latest source record: Nov 19, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

80

Planned (sponsor's estimate)

Start

Jan 2021

Primary completion

Mar 2022

Study completion Sep 2022

Sponsor

Sponsor type
Industry
First posted
Nov 19, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multicenter, Phase 2 study to evaluate the efficacy and safety of the anti- programmed cell death-1(PD-1) monoclonal antibody F520 in participants with locally advanced or metastatic Urothelial Cancer (UC).

Conditions

  • Locally Advanced or Metastatic Urothelial Cell Carcinoma

Interventions

  • F520Drug

    200mg,Q3W

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Objective Response Rate (ORR) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as assessed by the investigatorTime frame: Approximately 24 months

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.